These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7684157)

  • 1. Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study.
    Christensen MM; Bendix Holme J; Rasmussen PC; Jacobsen F; Nielsen J; Nørgaard JP; Olesen S; Noer I; Wolf H; Husted SE
    Scand J Urol Nephrol; 1993; 27(1):39-44. PubMed ID: 7684157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study.
    Bendix Holme J; Christensen MM; Rasmussen PC; Jacobsen F; Nielsen J; Nørgaard JP; Olesen S; Noer I; Wolf H; Elkjaer Husted S
    Scand J Urol Nephrol; 1994 Mar; 28(1):77-82. PubMed ID: 7516576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM; Klarskov P
    BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction.
    Chapple CR; Carter P; Christmas TJ; Kirby RS; Bryan J; Milroy EJ; Abrams P
    Br J Urol; 1994 Jul; 74(1):50-6. PubMed ID: 7519112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.
    Gillenwater JY; Conn RL; Chrysant SG; Roy J; Gaffney M; Ice K; Dias N
    J Urol; 1995 Jul; 154(1):110-15. PubMed ID: 7539854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
    Andersen M; Dahlstrand C; Høye K
    Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies.
    Mobley DF; Kaplan S; Ice K; Gaffney M; Dias N
    Int J Clin Pract; 1997; 51(5):282-8. PubMed ID: 9489085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile of doxazosin in patients with benign prostatic hyperplasia.
    Janknegt RA
    Scand J Urol Nephrol Suppl; 1995; 168():21-7. PubMed ID: 7541548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies.
    Abrams P
    Eur Urol; 1997; 32(1):39-46. PubMed ID: 9266230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
    Chung BH; Hong SJ; Lee MS
    Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Kim JH; Contreras BA; Steinberg GD; Rukstalis DB
    Urology; 1996 Jun; 47(6):840-4. PubMed ID: 8677574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
    Roehrborn CG; Siegel RL
    Urology; 1996 Sep; 48(3):406-15. PubMed ID: 8804494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
    Xue Z; Zhang Y; Ding Q; He Z; Wang J; Xu K
    Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Frusemide plus doxazosin therapy for nocturia in patients with BPH/LUTS].
    Huang SY; Zhu SX; Zeng BW; Zhu DS; Fang RJ
    Zhonghua Nan Ke Xue; 2010 Sep; 16(9):807-10. PubMed ID: 21171265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
    Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
    Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.